TODD is a “drug development company” that designs and develops protein-based and synthetic chemical pharmaceuticals based on innovative core technologies and business areas.

Our main business areas include the design of protein-based and synthetic chemical pharmaceuticals based on tertiary structures, the development of protein therapeutics for the treatment of metabolic diseases (such as obesity and diabetes), and the development of treatments for infections caused by multi-drug resistant bacteria.

We possess a variety of technologies and capabilities, including the development of protein therapeutics for the treatment of obesity and non-alcoholic steatohepatitis (NASH) (such as FGF21). Notably, we have technological excellence in protein drug purification methods using thermostability, as well as in the discovery and optimization of inhibitors against β-lactamase, an enzyme derived from multi-drug resistant pathogens.

Our main products and services include halisulfate, which exhibits β-lactamase inhibitory activity similar to avibactam already in clinical use, and an FGF21 variant (TODD-B-001), a candidate for the treatment of obesity and non-alcoholic steatohepatitis (NASH) in humans and pets, with 5.27 times the activity compared to the wild type. Additionally, we provide various services, such as structure-based protein and target-specific compound design services, recombinant production and purification services, and sales of recombinant proteins.

We are always committed to providing innovative, high-quality products and services and aim to grow into a global pharmaceutical company through continuous research, development, and collaboration.

TODD will continue to meet the diverse needs of customers by offering the highest quality and innovative technologies, striving for continuous development for a better future.